Fluvoxamine: an open pilot study in moderately obese female patients suffering from atypical eating disorders and episodes of bingeing.
The results of a small pilot study using Fluvoxamine (Faverin) in the treatment of non-vomiting bingeing female patients and women with bulimia nervosa is presented. Ten non-vomiting subjects and six with bulimia nervosa were treated on an open basis with Fluvoxamine 100-200 mg daily. Assessment was made using established questionnaires for severity of eating disorder and abnormality of mood. Five non-vomiting patients and three with bulimia nervosa completed the study. Non-vomiters showed a significant weight loss; a significant reduction in number of binges; a significant reduction in the scores on the BITE and the EAT; and a significant reduction in anxiety. Those with bulimia nervosa had a significant reduction in hunger and a reduction in depression which tended towards significance. Firm conclusions cannot be drawn from this study as it is an open pilot study of a small number of women. However, the results indicate that Fluvoxamine may have a role in the treatment of eating disorders where bingeing is a prominent symptom and that further research would be valuable. Comments are also made on the usefulness of various questionnaires designed to assess eating disorders.
Gardiner
H M
HM
Department of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, UK.
Freeman
C P
CP
Jesinger
D K
DK
Collins
S A
SA
D000293:Adolescent; D000328:Adult; D002032:Bulimia / Q000150:complications / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D001068:Feeding and Eating Disorders / Q000150:complications / Q000188:drug therapy*; D005260:Female; D016666:Fluvoxamine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D014839:Vomiting; D015431:Weight Loss
D016666:Fluvoxamine